" Small Pharma (TSXV:DMT) doses first patient in trial
Small Pharma Inc. (DMT) has dosed the first patient of its Phase IIa clinical trial for its lead N,N-dimethyltryptamine candidate, SPL026.
" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx
Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.
" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts
Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.
" Manganese X Energy (TSXV:MN) subsidiary Disruptive Battery reports positive results from research on fighting pathogens and biofilm
Manganese X Energy Corp. (MN) announced that its subsidiary has reported positive results from long-term research on fighting pathogens and biofilm.
" Vaxil Bio Ltd. (TSXV:VXL) signs letter of intent to acquire ShortWave Pharma Inc.
Vaxil (VXL), a biotech company, has signed a non-binding letter of intent to acquire a 100 per cent stake in ShortWave Pharma.
" Levitee Labs (CSE:LVT) appoints new Chief People Officer
Levitee Labs Inc (LVT) appoints Mohammed H Mosli, MD, FRCPC, ISAM, as Chief People Officer (CPO) of Levitee Clinics™ and Levitee Pharmacies™.
" Clearmind Medicine (CSE:CMND) appoints distinguished addiction experts to its scientific advisory board
Clearmind Medicine (CMND) has appointed professors Wim van den Brink and Gabriele Fischer to the company’s scientific advisory board.